To investigate the in vivo relevance of TLR4 signaling with IL-33 expression and NSCLC progression in clinical patients, NSCLC tissues with or without gram-negative bacterial infection were analyzed for TLR4, IL-33 and CD133 expressions. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.